Michael Alexander Smith Sells 4,407 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Michael Alexander Smith sold 4,407 shares of Insmed stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total transaction of $298,838.67. Following the completion of the transaction, the insider now directly owns 92,203 shares in the company, valued at $6,252,285.43. This trade represents a 4.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Alexander Smith also recently made the following trade(s):

• On Wednesday, May 14th, Michael Alexander Smith sold 409 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $26,834.49.

Insmed Stock Performance

Shares of INSM stock opened at $67.22 on Friday. The stock has a market capitalization of $12.22 billion, a PE ratio of -12.03 and a beta of 0.84. The business’s 50 day simple moving average is $71.68 and its 200 day simple moving average is $73.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same period in the prior year, the company posted ($1.06) earnings per share. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently made changes to their positions in the business. Park Avenue Securities LLC boosted its holdings in shares of Insmed by 42.1% during the 4th quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company’s stock worth $549,000 after buying an additional 2,358 shares in the last quarter. Atomi Financial Group Inc. raised its position in shares of Insmed by 6.6% during the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company’s stock worth $1,710,000 after purchasing an additional 1,526 shares during the period. Nisa Investment Advisors LLC grew its position in Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 183 shares during the period. Avior Wealth Management LLC bought a new stake in Insmed during the 4th quarter valued at $157,000. Finally, Blue Trust Inc. raised its holdings in Insmed by 25.7% during the fourth quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 503 shares during the last quarter.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. JPMorgan Chase & Co. boosted their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Truist Financial raised their price target on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Bank of America lifted their price target on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. Finally, UBS Group decreased their target price on shares of Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.